πŸ‡ΊπŸ‡Έ FDA
Patent

US 11370803

Heteroaryl plasma kallikrein inhibitors

granted A61PA61P29/02

Quick answer

US patent 11370803 (Heteroaryl plasma kallikrein inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P29/02